Embed Size (px)
Citation preview
Warsaw, 12th May 2016
Results summary Q1 2016
Agenda
page 2 | RESULTS’ SUMMARY | Q1 2016
• Summary Q1 2016
• Market and financial results
• Forecast execution after Q1 and shares division
• New business areas
• Challenges for further quarters 2016
Results’ summary Q1 2016*
page 3 | RESULTS’ SUMMARY | Q1 2016
Net debt/EBITDA
114 million/155 million
=0,74
PLN 35.2 million
net profit
with 7% growth YoY
PLN 52.3 million
EBITDA
with 12%
growth YoY
* Results do not include the non-recurring items
Growing market of pharmaceuticals wholesale
page 4 | RESULTS’ SUMMARY | Q1 2016
6,51
5,996,24
6,47
7,12
6,38 6,44 6,57
7,49
1,7%4,4% 4,9%
9,9% 9,3% 6,9%3,5% 1,6% 5,2%
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q
Value of pharmaceutical wholesale market by quarters and YoY quarterly
dynamics Q1 2014 – Q1 2016 (PLN billion)
• Market dynamics in the first quarter higher than the expectations from the beginning of 2016
• The impact of weather conditions on the market’s value growth
2014 2015 2016
NEUCA’s market position
page 5 | RESULTS’ SUMMARY | Q1 2016
25,0
28,5
30,330,1
29,2 29,3
28,4
[WARTOŚĆ]
28,3
Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016
Quarterly shares of NEUCA Group in the pharmaceuticals wholesale market
in Q1 2014 – Q1 2016 (%)
• Significant increase of market shares in the segment of independent from 28.7% at the end of
2015 to 29.3% at the end of March 2016
• Conscious resignation from servicing the least profitable contracts in the pharmacy chains’
segment
Our mission
page 6 | RESULTS’ SUMMARY | Q1 2016
We provide a better future to all
independent pharmacies in
Poland
Clients’ satisfaction* - NEUCA a quality leader
page 7 | RESULTS’ SUMMARY | Q1 2016* Data from the Pharmaceutical Monitor published by IMS for Q1 2016
Complaint services
Telemarketing servicesTransport services Logistics services
4,48
4,19
4,09
NEUCA Pelion Farmacol
4,55
4,37
4,31
NEUCA Pelion Farmacol
4,57
4,35 4,33
NEUCA Pelion Farmacol
4,43
4,29
4,23
NEUCA Pelion Farmacol
4,26
4,14 4,13
NEUCA Pelion Farmacol
Regular offer Promotional offer4,28
4,154,12
NEUCA Pelion Farmacol
page 8 | RESULTS’ SUMMARY | Q1 2016
Assortment widthSupply continuity
4,28
4,22
4,16
NEUCA Pelion Farmacol
4,34
4,244,27
NEUCA Pelion Farmacol
Client’s satisfaction* - NEUCA a quality leader
* * Data from the Pharmaceutical Monitor published by IMS for Q1 2016
Trade conditions Sense of security
4,41
4,324,33
NEUCA Pelion Farmacol
4,43
4,35
4,33
NEUCA Pelion Farmacol
page 9 | RESULTS’ SUMMARY | Q1 2016
FINANCIAL
RESULTS
Q1 2016
Sales revenues [PLN million]
page 10 | RESULTS’ SUMMARY | Q1 2016
1 885 1 859
1Q 2015 1Q 2016
-1%
Operating profit and EBITDA*
page 11 | RESULTS’ SUMMARY | Q1 2016
EBIT
[PLN million]
39,8
45,0
1Q 2015 1Q 2016
+13%
• Profitability growth of operating activity in Q1 2016 by 15%
PLN 52.3 million
EBITDA
in Q1
+12%YoY
* Results do not include the non-recurring items
Growth and net profit*
page 12 | RESULTS’ SUMMARY | Q1 2016
• Lack of non-recurring items in the first quarter
Growth profit
[PLN million]
Net profit
[PLN million]
39,344,3
Q1 2015 Q1 2016
+13%
• Decrease of financial costs by 7%
* Results do not include the non-recurring items
32,935,2
Q1 2015 Q1 2016
+7%
Private label products sales and net profit growth
page 13 | RESULTS’ SUMMARY | Q1 2016
21,5
26,5
1Q 2015 1Q 2016
Sales revenues
[PLN million]
+23%
• 455 products in the portfolio at the end of Q1 2016; growth by 9% YoY
• Optimisation of the existing products’ portfolio
5,3
6,0
1Q 2015 1Q 2016
+13%
Net result
[PLN million]
FORECAST
EXECUTION
AFTER Q1
AND PROFITS
DIVISION
page 14 | RESULTS’ SUMMARY | Q1 2016
2016
Net results' forecast execution after the Q1 2016
GROUP’S NET PROFIT
35.2million PLN
RESULTS’ SUMMARYpage 15
32% execution
Forecast for 2016 r.:
PLN 110 million
Shares’ division for 2015
page 16 | RESULTS’ SUMMARY | Q1 2016
2 702 2 702
4 8535 840
7 300
8 832
10 157
11 825
14 553
17 278
19 138
22 139
1,00 1,00
1,23
1,48
1,85 2,00
2,30
2,60
3,20
3,80
4,33
5,00
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Dividend value [PLN thousand]
Dividend value per share [PLN]
• Dividend day: 7th May; dividend payment date: 20th May
• Redemption of more than 86 company’s own shares
CAGR
17,4%
NEW BUSINESS
AREAS
page 17 | RESULTS’ SUMMARY | Q1 2016
1
x
3
5
page 18 | RESULTS’ SUMMARY | Q1 2016
Primary care outpatient clinics Świat Zdrowia
8
9
• Over PLN 47 million invested in 31 premises in 6 regions
• Access to over 80 thousand patients
• Investment in Medical Management (8 clinics in Warsaw and neighbourhood)
• Planned investments worth PLN 30 million in 2016, nearly 30% of the plan realised in Q1
5Number of clinics in a given region
page 19 | RESULTS’ SUMMARY | Q1 2016
Clinical trials
• Leader’s position on the Polish market of clinical trials with 8 clinical trials’ centres
• Executed buyout of the minority shareholders in Medica Pro Familia and planned
withdrawal od NewConnect from the market
100 clinical trials
conducted by the centres
within the NEUCA Group
in 2015
page 20 | RESULTS’ SUMMARY | Q1 2016
Investments in start-ups
• Diabdis device implementation at the beginning of May 2016
• Software Mediporta introduction to nearly 200 clinics
• Acquisition of Ortopedio.pl at the beginning of 2016, an Internet distributor of rehabilitation and
orthopaedic equipment
• Search and selection of projects by the dedicated team - NEUkubator
3 investments
executed in the last
couple of months
CHALLENGES
FOR FURTHER
QUARTERS 2016
page 21 | RESULTS’ SUMMARY | Q1 2016
Challenges for further quarters 2016
page 22 | RESULTS’ SUMMARY | Q1 2016
CREATION OF
CLINICS’ CHAIN
GROWTH OF
PRIVATE LABEL
PRODUCTS’ SALE
KEY
CHALLENGES
WORK ON
FURTHER
IMPROVEMENT
OF CLIENT’S
SATISFACTION
EXECUTION OF
BUDGET TARGETS
DEVELOPMENT
OF CLINICAL
TRIALS AND
IMPLEMENTATION
OF
DIABDIS PROJECT
USE OF SYNERGIES
IN NEW BUSINESSES
FOR PATIENTS
WORK ON
PLATFORM FOR
PHARMACEUTICAL
ORDERS
THANK YOU
FOR YOUR
ATTENTION!
